These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2024935)

  • 1. A review of the role of established tumour markers.
    Beastall GH; Cook B; Rustin GJ; Jennings J
    Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():5-18. PubMed ID: 2024935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological markers of cancer. Critical study].
    Bellet D; Bidart JM
    Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of tumour markers.
    Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
    Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic sensitivity, diagnostic specificity and predictive value of the determination of tumour markers.
    Wagener C
    J Clin Chem Clin Biochem; 1984 Dec; 22(12):969-79. PubMed ID: 6527105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [What importance do tumor markers have in life insurance medicine?].
    Binsack T; Kraus HK
    Versicherungsmedizin; 1990 Dec; 42(6):157-62. PubMed ID: 2291265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers].
    Fiebiger W; Wiltschke C
    Acta Med Austriaca; 2001; 28(2):33-7. PubMed ID: 11382139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marker proteins as indicators of tumour response to therapy.
    Bagshawe KD
    Br J Cancer Suppl; 1980 Apr; 4():186-90. PubMed ID: 6932925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical relevance of tumor markers].
    Lamerz R
    Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of novel tumour markers.
    Rhodes JM
    Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
    Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
    Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
    Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.